ArticleGenome biology2026
Updates to the reference genome alter the detection and direction of genes differentially expressed in Alzheimer's disease.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's Disease gene expression studies often rely on the reproducibility of known disease associations to build confidence in novel discoveries. This approach assumes that true biological variation associated with Alzheimer's Disease is robust to a range of technical and biological confounders that likely differ across experiments. Here, we systematically assess the impact of an important yet frequently overlooked technical confounder in Alzheimer's Disease differential expression analysis: changes in gene quantification resulting from ongoing updates to the human genome reference and transcriptome annotations.
resultsTo investigate this, gene expression in a large brain transcriptomic dataset from Alzheimer's Disease patients and controls (ROSMAP) was quantified using five transcriptome annotations mapped across a broad range of human genome references, from NCBI36 to CHM13v2.0. Although nearly all genes exhibit significant differences in expression between reference pairs (i.e., were differentially quantified), genome-wide Alzheimer's Disease differential expression signatures remain highly concordant across references. Notably, while a core set of significantly differentially expressed Alzheimer's Disease genes is largely conserved across references, reference-specific Alzheimer's Disease-associated genes are enriched for pathways known to be involved in the disease. Genes whose direction of association with Alzheimer's Disease significantly differs across references are also identified, highlighting the potential influence of reference choice on Alzheimer's Disease-relevant genes and pathways. All results were replicated in an independent transcriptomics dataset (MSBB) derived from the same brain region.
conclusionsThese findings demonstrate that reference genome choice impacts the identification and interpretation of specific Alzheimer's Disease-associated genes, despite overall reproducibility of genome-wide differential expression signatures, underscoring the critical importance of reference selection in Alzheimer's Disease transcriptomic studies.
Indexed as
Identifiers
43026550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.